LIXT Lixte Biotechnology Holdings, Inc.
Healthcare$5.65-3.91%ClosedMarket Cap: $70.0M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
8.06
P/S
0.00
EV/EBITDA
-9.63
DCF Value
$-8.16
FCF Yield
-6.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-125.6%
ROA
-66.9%
ROIC
-62.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-2.0M | $-1.9M | $— | — |
| Q4 null | $0.00 | NaN% | $-1.8M | $-2.5M | $— | — |
| FY null | $0.00 | NaN% | $-5.1M | $-6.0M | $— | — |
| Q3 null | $0.00 | NaN% | $-1.8M | $-2.0M | $— | — |
| Q2 null | $0.00 | NaN% | $-774.8K | $-775.7K | $— | — |
| Q1 null | $0.00 | NaN% | $-706.9K | $-709.6K | $— | — |
| Q4 null | $0.00 | NaN% | $-613.5K | $-617.7K | $— | — |
| FY null | $0.00 | NaN% | $-3.6M | $-3.6M | $— | — |
| Q3 null | $0.00 | NaN% | $-983.3K | $-986.0K | $— | — |
| Q2 null | $0.00 | NaN% | $-1.0M | $-1.0M | $— | — |
| Q1 null | $0.00 | NaN% | $-966.9K | $-971.3K | $— | — |
| Q4 2023 | $0.00 | NaN% | $-1.0M | $-1.0M | $-0.46 | — |